Academia Sinica Of Taiwan, Novartis Collaborate On Medical Biotech R&D
This article was originally published in PharmAsia News
Taiwan's Academia Sinica and Novartis have agreed to collaborate on medical biotechnology over the next five years, with two Taiwan researchers working with units of the Swiss-based drug maker, including in China and Singapore.
You may also be interested in...
For the first time, the US FDA granted an emergency use authorization to a device that allows for the home collection of saliva for COVID-19 diagnosis. See what Scott Rabuka, senior director of molecular products at DNA Genotek, which developed the test, said about it here.
Deputy CEO Nicolas Hieronimus will take L’Oreal’s helm beginning in May 2021, with Jean-Paul Agon continuing as chairman, the firm announced on 14 October. The Estee Lauder Companies hires PepsiCo’s Gibu Thomas to lead its online business, and Coty appoints its first chief digital officer.
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.